相关实验视频
Updated: Jul 15, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
一种组织等离子体激活剂/P-选择因融合蛋白是一种有效的血栓解压剂
K Fujise1, B M Revelle, L Stacy
1Department of Internal Medicine, University of Texas-Houston Health Science Center 77030, USA. kfujise@heart.med.uth.tmc.edu
Circulation
|February 4, 1997
概括
工程组织等离子体激活剂 (TPA) /P-选择因融合蛋白显示出有效的血栓溶解活性,类似于单独的TPA. 这些新奇的嵌合蛋白显示出向输送到血栓的潜力,增强治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 血栓形成的研究研究
背景情况:
- P-选择因在激活的内皮细胞和血小板上表达.
- 假设TPA/P-selectin融合蛋白可以将TPA向血栓.
- 研究了竞争性抑制白细胞与P-selectin.in结合的潜力.
研究的目的:
- 开发和评估TPA/P-selectin融合蛋白用于血栓溶解疗法.
- 评估这些嵌合蛋白的向输送和治疗疗效.
- 为了确定融合蛋白是否比原生TPA提供优势.
主要方法:
- 使用baculovirus载体表达的全长TPA抑制剂-1-耐药TPA (TPAIR) 和融合结构 (P280IR,P121IR).
- 通过金属离子染色学净化重组蛋白质.
- 在体外 (凝块溶解试验) 和体内 (大鼠中腔动脉模型) 评估血栓解压活性.
主要成果:
- 在试验室中,TPAIR,P280IR和P121IR表现出类似的凝块溶解功效.
- 在体内研究显示,所有测试分子的循环流变化显著和可比减少.
- 在接受治疗的动物中没有观察到明显的出血并发症.
结论:
- 化学蛋白P280IR和P121IR在体外和体内具有与TPAIR相似的凝块溶解活动.
- 这些融合蛋白与P-选择蛋白连接体结合,这表明有针对性血栓溶解的潜力.
- 需要对较大的动物模型进行进一步的研究,以探索临床治疗潜力.
相关概念视频
Selectins
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

